ANAPTYSBIO INC
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
On January 9, 2025, John Schmid, adirector of the company, terminated a written 10b5-1 Plan dated August 30, 2024.
On January 10, 2025, Daniel Faga, chief executive officer of the company, entered into a written plan for the potential sale of common stock. The plan was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. No shares were sold under the plan and it was subsequently terminated on March 18, 2025, before the 90 day “cooling off period”.
On March 18, 2025, Dennis Mulroy, chief financial officer of the company, terminated a written 10b5-1 Plan dated June 14, 2024.
On March 18, 2025, Eric Loumeau, chief legal officer of the company, terminated a written 10b5-1 Plan dated June 10, 2024.
Other than as disclosed above, during the three months ended March 31, 2025, none of the company’s directors or officers adopted orterminated any “Rule 10b5-1 trading arrangements” or any “non-Rule 10b5-1 trading arrangements,” as each term is defined in Item 408 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.